Citable filing context

EW filing events and research context

Server-rendered

EW's research view summarizes recent SEC filing context, starting with mda_quarterly from May 6, 2026.

EW filing events and research context
FiledItemContext
May 6, 2026mda_quarterlyNet sales increased 16.7% to $1.6 billion for the first quarter of 2026, driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). Growth was specifically fueled by the SAPIEN 3 Ultra RESILIA valve, the PASCAL repair system, and the EVOQUE tricuspid valve replacement system, with the most significant regional expansion occurring in Europe. While gross profit rose, margins were pressured by foreign currency fluctuations and manufacturing costs associated with new therapy expansions. Research and development spending increased to support implantable heart failure management. Strategic shifts included the $128.9 million acquisition of Autus Valve Technologies for pediatric pulmonary valves and the divestiture of the Critical Care product group. Financial headwinds include a $123.6 million impairment loss on a VIE investment and potential tax liabilities from ongoing IRS transfer pricing disputes. Furthermore, the company expects approximately $70 million in additional tax expenses in 2026 due to OECD Pillar Two global minimum tax rules. Operational risks persist regarding U.S. trade tariffs and patent litigation involving SAPIEN 3 Ultra and PASCAL products. The company returned $520.1 million to shareholders through common stock repurchases.
Feb 25, 2026businessEdwards Lifesciences operates in a highly regulated, innovation-driven environment where success depends on maintaining strong relationships with key physicians and research institutions. The company’s core business, particularly its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) groups, relies on hospital systems having the necessary facilities and staffing to perform these procedures. A shift toward competitor products or hospital resource constraints poses a material risk to revenue. Operational risks are significant, as the company depends on third-party vendors for raw materials and manufacturing, often utilizing single-source suppliers. This supply chain vulnerability is compounded by global macroeconomic factors, including inflationary pressures, currency fluctuations, and evolving international trade policies, such as tariffs. Furthermore, the company faces intense pricing pressure due to healthcare industry consolidation and the increasing focus of third-party payors on cost containment. Regulatory and legal hurdles remain central to the business model. The company must navigate rigorous FDA and EU MDR compliance, manage complex intellectual property litigation, and adhere to evolving data privacy laws. Additionally, the company’s reliance on bovine tissue for heart valves introduces specific biological safety risks, while the integration of emerging technologies like AI presents both competitive opportunities and new cybersecurity and regulatory challenges.
Feb 25, 2026mdaEdwards Lifesciences (EW) reported 2025 net sales of $6.1 billion, an 11.5% increase over 2024, driven primarily by growth in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. TAVR remains the company’s core revenue driver, accounting for 74% of net sales, supported by the SAPIEN 3 platform and recent FDA approval for use in asymptomatic severe aortic stenosis patients. The TMTT portfolio, featuring the PASCAL repair system, EVOQUE tricuspid replacement, and SAPIEN M3 mitral replacement, grew to 9% of net sales as the company expands its footprint in complex valve disease. Financial performance in 2025 was impacted by increased personnel costs, litigation expenses, and impairment charges, which pressured net income despite top-line growth. The company continues to prioritize R&D, investing 18% of net sales into clinical evidence generation and innovation, particularly for its RESILIA tissue technology, which is central to its Surgical Structural Heart segment. Strategic operations were reshaped by the 2024 divestiture of the Critical Care group and the 2025 sale of a non-core product group. Key risks include intense competition from Medtronic and Abbott, reliance on third-party reimbursement, and the ongoing challenge of maintaining hospital procedure volumes amid staffing and facility constraints.

Source: SEC EDGAR filing text and events; period May 6, 2026; filed May 6, 2026.

Continue research

Keep researching EW

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →